No abstract

No abstract

In this case series, we report for the first time in the literature in a cohort, the positive response to oral or topical antifungals for atopic dermatitis patients treated with Dupilumab that developed Dupilumab facial redness, supporting the Malassezia hypersensitivity theory.adverse effects, atopic dermatitis, Dupilumab, facial redness, head and neck dermatitis, Malassezia Dupilumab has shown to be an effective treatment for moderate to severe atopic dermatitis (AD). 1 Adverse events (AE) that have been described in AD patients treated with Dupilumab include injection site reactions, cold sores, hypersensitivity, anaphylaxis, and eye problems mostly secondary to Dupilumab ocular surface disease (DOSD). 1 AD patients can also develop Dupilumab facial redness (DFR), an AE described after approval, with an unknown etiopathogenesis. 2 Four theories have been proposed to explain DFR: hypersensitivity reaction to Dupilumab, site-specific treatment failure, seborrheic dermatitis-like reaction to Malassezia spp., paradoxical flare of contact dermatitis, or a combination of these. 3